|
When
“Fidgety Philip” grows up, the problems of attention
deficit disorder can multiply into loss of nearly a
month’s work per year. v Long seen as a problem for
children, attention deficit hyperactivity disorder
(ADHD) was first described in 1845 by Dr. Heinrich
Hoffman, who wrote “The Story of Fidgety Philip.”
More
recently, it has been recognized as continuing into
adulthood for some people, and new research seeks to
estimate the effect of ADHD on workers.
This
lack of ability to concentrate costs the average adult
sufferer 22.1 days of “role performance,” per year,
including 8.7 extra days absent, according to
researchers led by Dr. Ron de Graaf of the Netherlands
Institute of Mental Health and Addiction.
It might
be cost-effective for employers to screen workers for
ADHD and provide treatment, the researchers suggest.
“There
were many more people than most of us who have done
these studies had expected,” that were affected by adult
ADHD, said Dr. Ronald C. Kessler of Harvard University,
a coauthor of the report. “People don’t come for
treatment for this....it’s kind of one of those hidden
things,” he said in a telephone interview.
“It’s an
enormous impairment,” Kessler said, citing absences,
accidents and low performance on the job.
Kessler
said he had worked with workers suffering depression and
found that treatment costing $1,000 could help prevent
$4,000 in lost productivity.
“It sure
looks like the effect would be as big, if not bigger,
for ADHD,” he said. “We’re looking around for an
employer or two who might be willing to give this a
try.” Linda S. Anderson, president of the Adult
Attention Deficit Disorder Association, said workplace
assistance and treatment can be vital,
Most
people think of ADHD as a children’s problem, but when
it continues into adulthood people have a problem coping
with the workplace and need assistance, said Anderson,
who was not part of the research team.
The new
study may underestimate the adult rate of ADHD, she
said, noting that many victims may not have jobs. Those
who do often struggle to keep up, but there are
treatments available, she said.
The
majority of the lost performance was associated with
reductions in quantity and quality of work rather than
actual absenteeism, the researchers said.
Many
employers assume occasional absences are part of the
cost of doing business, but the paper noted that,
“typically they expect their workers to be working when
they are on the job.”
To find
that most of the ADHD-related loss occurs on days when
the worker is present is both striking and disturbing
from an employer perspective, the authors said.
Researchers interviewed 7,075 workers aged 18 to 44 in
10 countries, concluding that an average of 3.5 percent
had ADHD. Their findings are published in Tuesday’s
online edition of the journal Occupational and
Environmental Medicine.
In 2006,
a study led by Kessler estimated that 4.4 percent of
adults aged 18 to 44 in the United States experience
ADHD symptoms and some disability.
The new
research estimated the US rate at 4.5 percent among
workers, costing an average of 28.3 days performance.
The
highest rate was for
France,
6.3 percent, but the lost time was lower at 20.1 days.
Other
countries studied and ADHD rates among adults, and
estimated days lost per affected worker, were Lebanon,
0.9 percent, 19.4 days; Spain, 1.3 percent, 1.1 days;
Colombia, 1.9 percent, 29.4 days; Mexico, 2.4 percent,
6.1 days; Italy, 3.4 percent, 22.2 days; Germany, 3.5
percent, 13.6 days; Belgium, 3.7 percent, 16.5 days;
Netherlands, 4.9 percent, performance improved.
The
researchers were unable to explain why the ADHD affected
workers in the Netherlands had improved performance
rather than the declines seen in every other country
studied.
“We
periodically find one of those blips, we just don’t know
why,” Kessler said.
In a
separate study issued earlier this month, researchers
led by Kessler reported that major mental disorders cost
the US at least $193-billion annually in lost earnings
alone. That study was published in the American Journal
of Psychiatry.
The new
international study was supported by the World Health
Organization, US National Institute of Mental Health,
John D. and Catharine T. MacArthur Foundation, the
Pfizer Foundation, US Public Health Service, Fogarty
International Center, Pan American Health Organization,
Eli Lilly and Co., Ortho-McNeil Pharmaceutical Inc.,
GlaxoSmithKline and Bristol-Myers Squibb Co.. |